205 related articles for article (PubMed ID: 21721203)
1. [PARP inhibitors: new therapeutic agents in breast and ovarian cancer].
Mercier-Vogel L; Bodmer A; Castiglione M
Rev Med Suisse; 2011 May; 7(296):1137-40. PubMed ID: 21721203
[TBL] [Abstract][Full Text] [Related]
2. The potential of PARP inhibitors in genetic breast and ovarian cancers.
Drew Y; Calvert H
Ann N Y Acad Sci; 2008 Sep; 1138():136-45. PubMed ID: 18837894
[TBL] [Abstract][Full Text] [Related]
3. The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: current status and future directions.
Chionh F; Mitchell G; Lindeman GJ; Friedlander M; Scott CL
Asia Pac J Clin Oncol; 2011 Sep; 7(3):197-211. PubMed ID: 21884432
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.
Drew Y; Mulligan EA; Vong WT; Thomas HD; Kahn S; Kyle S; Mukhopadhyay A; Los G; Hostomsky Z; Plummer ER; Edmondson RJ; Curtin NJ
J Natl Cancer Inst; 2011 Feb; 103(4):334-46. PubMed ID: 21183737
[TBL] [Abstract][Full Text] [Related]
5. BRCA in breast cancer: from risk assessment to therapeutic prediction.
Diamond JR; Borges VF; Eckhardt SG; Jimeno A
Drug News Perspect; 2009 Dec; 22(10):603-8. PubMed ID: 20140280
[TBL] [Abstract][Full Text] [Related]
6. [Role of oncogenetics in the treatment of breast and ovarian cancer].
Langmár Z; Németh M
Orv Hetil; 2011 Jul; 152(30):1214-5. PubMed ID: 21733796
[No Abstract] [Full Text] [Related]
7. PARP inhibitors: will the new class of drugs match the hype?
Tuma RS
J Natl Cancer Inst; 2009 Sep; 101(18):1230-2. PubMed ID: 19738163
[No Abstract] [Full Text] [Related]
8. PARP inhibitors in breast cancer: BRCA and beyond.
Rios J; Puhalla S
Oncology (Williston Park); 2011 Oct; 25(11):1014-25. PubMed ID: 22106552
[TBL] [Abstract][Full Text] [Related]
9. PARP inhibition in breast cancer.
Garber J
Clin Adv Hematol Oncol; 2009 Sep; 7(9):573-5. PubMed ID: 20020667
[No Abstract] [Full Text] [Related]
10. PARP inhibition in BRCA-mutated breast and ovarian cancers.
Chan SL; Mok T
Lancet; 2010 Jul; 376(9737):211-3. PubMed ID: 20656109
[No Abstract] [Full Text] [Related]
11. PARP inhibitors in breast cancer.
Telli ML; Ford JM
Clin Adv Hematol Oncol; 2010 Sep; 8(9):629-35. PubMed ID: 21157412
[TBL] [Abstract][Full Text] [Related]
12. PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers.
Carden CP; Yap TA; Kaye SB
Curr Opin Oncol; 2010 Sep; 22(5):473-80. PubMed ID: 20485165
[TBL] [Abstract][Full Text] [Related]
13. [Poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA1/2 cancer therapy].
Kluzek K; Białkowska A; Koczorowska A; Zdzienicka MZ
Postepy Hig Med Dosw (Online); 2012 Jun; 66():372-84. PubMed ID: 22706123
[TBL] [Abstract][Full Text] [Related]
14. [Molecular basis of breast cancer related to BRCA 1 and BRCA2 genes: characteristics and targeting therapy].
Levanat S; Cvok ML
Lijec Vjesn; 2010; 132(1-2):34-7. PubMed ID: 20359158
[TBL] [Abstract][Full Text] [Related]
15. Challenges to the development of new agents for molecularly defined patient subsets: lessons from BRCA1/2-associated breast cancer.
Domchek SM; Mitchell G; Lindeman GJ; Tung NM; Balmaña J; Isakoff SJ; Schmutzler R; Audeh MW; Loman N; Scott C; Friedlander M; Kaufman B; Garber JE; Tutt A; Robson ME
J Clin Oncol; 2011 Nov; 29(32):4224-6. PubMed ID: 21931031
[No Abstract] [Full Text] [Related]
16. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
17. [PARP inhibitors--theoretical basis and clinical application].
Dębska S; Kubicka J; Czyżykowski R; Habib M; Potemski P
Postepy Hig Med Dosw (Online); 2012 May; 66():311-21. PubMed ID: 22706117
[TBL] [Abstract][Full Text] [Related]
18. [Breakthrough breast cancer treatment--PARP inhibitor, BRCA, and triple negative breast cancer].
Hashimoto K; Tamura K
Gan To Kagaku Ryoho; 2010 Jul; 37(7):1187-91. PubMed ID: 20647696
[TBL] [Abstract][Full Text] [Related]
19. PARP inhibitors in ovarian cancer: current status and future promise.
Liu JF; Konstantinopoulos PA; Matulonis UA
Gynecol Oncol; 2014 May; 133(2):362-9. PubMed ID: 24607283
[TBL] [Abstract][Full Text] [Related]
20. [PARP inhibitors and breast cancer: update and perspectives].
Gonçalves A
Bull Cancer; 2012 Apr; 99(4):441-51. PubMed ID: 22450359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
